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Abstract
Introduction Metastasis is a complex process involving loss of
adhesion, migration, invasion and proliferation of cancer cells.
Cell adhesion molecules play a pivotal role in this phenomenon
by regulating cell–cell and cell–matrix interactions. CD146
(MCAM) is associated with an advanced tumor stage in
melanoma, prostate cancer and ovarian cancer. Studies of
CD146 expression and function in breast cancer remain scarce
except for a report concluding that CD146 could act as a tumor
suppressor in breast carcinogenesis.
Methods To resolve these apparent discrepancies in the role of
CD146 in tumor cells, we looked at the association of CD146
expression with histoclinical features in human primary breast
cancers using DNA and tissue microarrays. By flow cytometry,
we characterized CD146 expression on different breast cancer
cell lines. Using siRNA or shRNA technology, we studied
functional consequences of CD146 downmodulation of MDA-
MB-231 cells in migration assays. Wild-type, mock-transfected
and downmodulated transfected cells were profiled using
whole-genome DNA microarrays to identify genes whose
expression was modified by CD146 downregulation.
Results Microarray studies revealed the association of higher
levels of CD146 with histoclinical features that belong to the
basal cluster of human tumors. Expression of CD146 protein on
epithelial cells was detected in a small subset of cancers with
histoclinical features of basal tumors. CD146+ cell lines
displayed a mesenchymal phenotype. Downmodulation of
CD146 expression in the MDA-MB-231 cell line resulted in
downmodulation of vimentin, as well as of a set of genes that
include both genes associated with a poor prognosis in a variety
of cancers and genes known to promote cell motility. In vitro
functional assays revealed decreased migration abilities
associated with decreased CD146 expression.
Conclusions In addition to its expression in the vascular
compartment, CD146 is expressed on a subset of epithelial
cells in malignant breast. CD146 may directly or indirectly
contribute to tumor aggressiveness by promoting malignant cell
motility. Changes in molecular signatures following
downmodulation of CD146 expression suggest that CD146
downmodulation is associated with the reversal of several
biological characteristics associated with epithelial to
mesenchymal transition, and the phenomenon associated with
the metastatic process.
ER: estrogen receptor; FCS: fetal calf serum; mAb: monoclonal antibody; PR: progesterone receptor; RT-PCR: real-time polymerase chain reaction; Page 1 of 14
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Metastasis is a complex process involving loss of adhesion,
migration, invasion and proliferation of cancer cells that
receive signals and interact with the extracellular matrix, neigh-
boring cells and growth factors. Cell adhesion molecules play
a pivotal role in metastasis by regulating cell–cell and cell–
matrix interactions [1].
CD146 (or MCAM, Mel-CAM, MUC18, S-endo1) was first
described on malignant melanomas [2]. CD146 is a 113 kDA
membrane glycoprotein that belongs to the immunoglobulin
superfamily. It contains five immunoglobulin-like domains, one
transmembrane region and a short cytoplasmic tail. The pres-
ence of several protein kinase recognition motifs in the cyto-
plasmic domain suggests the involvement of CD146 in cell
signaling [3]. CD146 mediates homotypic and heterotypic
adhesion between cells, although the ligand or the counter
receptor is not known [4]. CD146 is a component of the inter-
endothelial junction [5], and is now recognized as a marker of
mesenchymal cells [6]. Its role in endothelial development is
suggested by studies in the zebra fish [7]. The direct or indi-
rect role of CD146 in cell migration has been suggested by
several observations [8]. A recent report supports the impor-
tance of CD146 as a marker of bone marrow stromal cells with
the ability to transfer the hematopoietic microenvironment to
heterotopic sites [9]. Finally, CD146 is expressed on a small
subset of activated T cells [10].
CD146 is structurally related to gicerin, a molecule that pro-
motes metastasis of lymphoma cells in chicken [11] and
metastasis of mouse mammary carcinoma cells [12]. Forced
expression of CD146 in nonmetastatic melanoma cell lines
increases their metastatic ability in mouse models [13]. More
recent reports indicate that CD146 is overexpressed on pros-
tate cancer cells [14], and that CD146 overexpression
increases metastasis of prostate cancer cells in nude mice
[15]. CD146 is associated with advanced tumor stage in ovar-
ian cancers and could be a poor-prognosis factor that predicts
early tumor relapse [16]. In pulmonary adenocarcinomas,
CD146 expression is associated with shorter patient survival
[17].
Antibodies against CD146 inhibit tumor growth of different
xenografted tumor models: melanoma [18] and leiomyosar-
coma, pancreatic cancer or hepatocarcinoma [19]. More
recently, vaccination against murine melanoma cells express-
ing CD146 was shown to protect mice from lethal doses of
melanoma cells [20].
Studies of CD146 expression and function in breast cancer –
the leading cause of cancer morbidity and mortality among
women – remain scarce, and mostly focus on circulating
endothelial cells [21] or on tumor neoangiogenesis [22]. A
previous report demonstrated that CD146 is expressed on
epithelial and myoepithelial cells, and on 100% of benign pro-
liferative epithelial lesions of the breast, but in only 18% of
breast carcinomas, leading to the conclusion that CD146
could act as a tumor suppressor in breast carcinogenesis
[23].
To resolve these apparent discrepancies in the role of CD146
in various models of malignancies, we further investigated
CD146 expression in malignant human breast tissues to deter-
mine whether CD146 was associated with any particular
tumor subtype, or biological or clinical feature. Our data sug-
gest a role for CD146 in cell motility and progression in breast
cancers, consistent with its role in other malignancies.
Materials and methods
Patients
Breast tumor specimens were obtained from consecutive can-
cer patients treated at our institution, following informed con-
sent and a review of the protocol by the Institut Paoli-
Calmettes Comité d'Orientation Stratégique (Institutional
Review Board). Histological types included ductal carcino-
mas, lobular, mixed, tubular, medullar and other types. The
median age of patients was 59 years (range 24 to 94 years).
Women were treated according to guidelines used in our insti-
tution: after surgery, 93% received locoregional radiotherapy,
51% received adjuvant chemotherapy (anthracyclin-based
regimen in most cases) and 52% received adjuvant hormono-
therapy (tamoxifen, most cases). Tumor tissues were obtained
before the initiation of systemic therapy.
Immunohistochemistry on breast cancer tissue 
microarrays
Tissue microarrays were prepared as described previously
[24], and were evaluated by the mean score of a minimum two
core biopsies for each case. Slides were evaluated under a
light microscope by two independent observers on the Spot
Browser device (Alphelys, Plaisir, France) and were rated by
the quick score [25], except for the tyrosine kinase receptor
ERBB2 status (HercepTest kit; Dako France S.A.S., Trappes,
France). Internal positive controls such as epidermis or benign
breast lobules were used. Estrogen receptor (ER) and proges-
terone receptor (PR) were considered positive when at least
1% of tumor cell nuclei were stained. ERBB2 staining was
considered positive when limited to a membrane staining of
more than 10% of tumor cells (scored as 1+, 2+ or 3+ accord-
ing to intensity). Protein overexpression was considered for
scores of 2+ and 3+. Epidermal growth factor receptor was
scored positive if any membranous invasive carcinoma cell
staining was observed. See Additional data file 1 for the mAbs
used in the present study.
Cell lines
Ten breast tumor cell lines were used in this study: BT-549,
Hs578T, MCF-7, MDA-MB-231, MDA-MB-436, MDA-MB-
453, T-47D, ZR-75-30 (all from American Type Culture Col-Page 2 of 14
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SUM159PT (Asterand, Detroit, MI, USA).
ZR-75-30, T47D, BrCA-MZ-02, MDA-MB-453, MDA-MB-
231, MDA-MB-436 and BT549 cells were cultured in RPMI
(Cambrex, Verviers, Belgium) supplemented with 10% heat-
inactivated FCS (Invitrogen, Paisley, UK). MCF-7 cells were
cultured in the same medium supplemented with insulin (30
μg/ml; Sigma-Aldrich, St Louis, MO, USA). Sum159PT cells
were cultured in the same medium (RPMI, FCS and insulin)
supplemented with hydrocortisone (1 μg/ml). Hs578T cells
were cultured in RPMI supplemented with 10% FCS, insulin
(30 μg/ml) and glucose (2.5 g/l). All of the culture media con-
tained 100 U/ml penicillin and 100 μg/ml streptomycin (Invit-
rogen).
The HBMEC cell line, a kind gift from B. Weksler (New York,
USA), is derived from adult human bone marrow endothelial
cells, following SV-40 immortalization, and was cultured as
previously described [27,28].
Flow cytometry
Analyses were conducted with a LSRII Flow cytometer (Bec-
ton-Dickinson Immunocytometry Systems, San Jose, CA,
USA). Cells were incubated with mAbs (see Additional data
file 1) for 30 minutes on ice, and with a phycoerythrin-labeled
goat anti-mouse antibody (Beckman-Coulter, Miami, FL, USA)
in case of unconjugated mAbs. Isotype controls were used to
exclude false positive cells. Dead cells were gated out by
staining with Dapi (1 μg/ml; Invitrogen).
Quantitative RT-PCR
Total RNA was isolated from 1 × 106 to 2 × 106 cells using an
RNA extraction kit (Macherey-Nagel GmBH & Co, Düren, Ger-
many), denatured at 65°C for 10 minutes and reverse-tran-
scribed using Superscript II reverse transcriptase (Invitrogen).
Quantitative RT-PCR was carried out using the LightCycler
2.0 instrument and software version 4.0 (Roche Diagnostics,
Meylan, France). The 20 μl reaction mixture contained 4 μl of
5× Master Mix (Roche Diagnostics), 0.5 μM each primer and
1 μl cDNA sample. After initial incubation at 95°C for 10 min-
utes, 60 cycles were carried out (10 s at 95°C, 10 s at 60°C,
and 20 s at 72°C). To confirm differential expression observed
with DNA microarray, the 21 downregulated genes were
quantified by RT-PCR. The primers are listed in Additional data
file 2.
In addition, the expression of 180 adhesion, migration and
cytoskeleton genes (see Additional data file 3) was tested
from 1 μg cDNA using SYBR Green reagent on an ABI7700
system (Applied Biosystems, Foster City, CA, USA). Specific
primers were designed using the Primer Express Software
(Applied Biosystems) and were spotted in 96-well plates,
which were made available to us through a collaboration with
Inserm U 576-Nice Régulations des réactions immunitaires et
inflammatoires. Gene expression was normalized for RNA con-
centration with four endogenous genes (GAPDH, HPRT, ubiq-
uitin, β-actin).
RNA-interference mediated gene silencing
siRNA duplexes directed against CD146 [Gen-
Bank:NM_006500] were synthesized by Invitrogen (see Addi-
tional data file 2). Two negative controls were used: a mutated
siRNA (si78mut) with a modification of four nucleotides, and a
siRNA that recognizes the green fluorescent protein gene
(siGFP).
Then 105 cells were plated in six-well culture dishes in 2.5 ml
medium without antibiotics. Cells were transfected with a mix-
ture of siRNA (10 nM) and Lipofectamine RNai/Max (Invitro-
gen) according to the manufacturer's protocol.
The 29mer shRNA expression vectors (see Additional data file
2) directed against CD146 were obtained from Origene Tech-
nologies, Inc. (Rockville, MD, USA). These vectors in pRS
plasmid were amplified and purified with the Nucleobond PC
100 Kit (Macherey-Nagel). MDA-MB-231 cells were plated at
3 × 105 cells in six-well plates. Transfections were performed
using Fugene-6 (Roche Diagnostics) as directed by the man-
ufacturer. Forty-eight hours after transfection, puromycin (0.8
μg/ml; Sigma-Aldrich) was added. Transfected cell lines were
grown in the presence of puromycin. Two negative control
shRNA expression vectors were used in this study: the original
vector plasmid [TR20003], and a vector containing a nonef-
fective shRNA cassette against green fluorescent protein
[TR30003].
Cell migration assays
Before migration, cells were starved overnight in RPMI
medium (Lonza, Walkersville, MD, USA). Migration was
observed in transwell culture inserts of 6.5 mm diameter and
8 μm pore filters (Greiner Bio-One SAS, Courtaboeuf,
France). Then 3 × 104 cells in 100 μl RPMI medium with 1%
FCS (Invitrogen) were seeded in the upper compartment, and
600 μl RPMI 10% FCS were added to the lower chamber.
Cells were allowed to migrate for 24 hours at 37°C. After
removing cells on the upper side of the transwell, cells on the
underside were stained with 0.1% crystal violet solution (Bec-
ton Dickinson) and were lysed with 10% acetic acid for quan-
tification by densitometric measurement at 550 nm. In some
experiments, cells were preincubated with an anti-CD146
mAb (S-Endo1; BioCytex, Marseilles, France) for 1 hour at
4°C and the mAb was present during the migration assay.
Experiments were carried out in triplicate.
For transmigration assays, 40,000 HBMEC cells were estab-
lished to confluence in 0.1% gelatin-coated transwells. Wild-
type (30,000 cells) or genetically modified MDA-MB-231 cells
in RPMI medium supplemented with 0.2% bovine serum albu-
min (Sigma-Aldrich) were seeded in the upper chamber. ThePage 3 of 14
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24 hours, staining was performed as for migration assays. In
order to account for the possible migration of HBMEC cells, a
blank well was included in all series.
For wound healing assays, 3.5 × 103 cells were seeded in 24-
well plates and were grown to confluence. Cells were
scrapped with a 200 μl micropipette tip (0 hours) and allowed
to migrate for 24 hours. Each wound area was photographed
(0 hours and 24 hours) using an Olympus IX70 inverted micro-
scope equipped with a digital camera (Olympus France,
Rungis, France). The percentage of the cell-free area was esti-
mated with the use of ImageJ software [29].
Gene expression profiling with DNA microarrays
Wild-type, mock-transfected and stably transfected cell lines
were profiled using whole-genome DNA microarrays. Gene
expression analyses were performed with Affymetrix U133
Plus 2.0 human oligonucleotide microarrays (Affymetrix, Santa
Clara, CA, USA) containing over 47,000 transcripts and vari-
ants, including 38,500 well characterized human genes. Prep-
aration of cDNA from 2 μg total RNA, hybridizations, washes
and detection were carried out as recommended by the sup-
plier. Scanning was performed with the Affymetrix GeneArray
scanner, and quantification with Affymetrix GCOS software.
Expression data were analyzed by the Robust Multichip Aver-
age method in R using Bioconductor and associated pack-
ages [30]. A filtering process removed from the dataset the
genes with low and poorly measured expression, retaining
18,041 probe sets. Supervised analysis compared expression
profiles from the three control cell lines with those from the two
experimental cell lines. In a first step, a Student's t test with
false discovery rate correction retained probe sets differen-
tially expressed between the two groups with a significance
threshold of P < 0.05. In a second step, we measured for each
significant probe set the fold change of mean expression lev-
els between the control group and the experimental group.
Results [GEO:GSE11951] were displayed simultaneously in
a volcanoplot [31].
Statistical analyses
Survival rates were estimated following the Kaplan–Meier
method. Overall survival was calculated from the date of diag-
nosis until the date of death and was compared between
groups with the log-rank test. Correlations between sample
groups and histoclinical factors were calculated using the
Fisher's exact test for qualitative variables with discrete cate-
gories. All statistical tests were two-sided at the 5% level of
significance. Statistical analyses were performed using the
survival package (version 2.30) in R software [32].
Results
CD146 is expressed in human primary breast tumors
The study of 635 untreated primary breast tumors aggregated
in two tissue microarrays revealed that 45 tumors (7%) were
positive for CD146 staining in the epithelial compartment (Fig-
ure 1a,b). Most CD146-positive tumors were ductal carcino-
mas (78%). CD146 expression was strongly associated with
high grade, with negativity for ER and PR, and with the triple-
negative (ER-/PR-/ERBB2-) phenotype. Association with posi-
tivity for epithelial growth factor receptor, p53, P-cadherin and
Moesin, together with negativity for GATA-3 and BCL2, indi-
cated a pattern of basal tumors (Table 1) [33].
Analysis of our previously published gene expression data of
227 breast cancer samples profiled using oligonucleotide
microarrays [34] also supported this conclusion: an expanded
view of the hierarchical clustering of our tumor series showed
that CD146 is included in a stromal gene cluster enriched in
mesenchymal and vascular genes (see Additional data file 4),
and is overexpressed in basal tumors as compared with lumi-
nal tumors (Figure 2). With the median expression level of the
corresponding probe set across all tumors as the cutoff point
for defining a rich or poor tumor for CD146, CD146-rich
tumors were more frequently grade III, ER-negative or PR-neg-
ative, and displayed a basal phenotype in 41% of cases versus
22% for CD146-poor tumors (Table 1).
Figure 1
CD146 protein expression in human primary breast cancer and specific survival  expre sion in human prima y breast cancer and 
specific survival. Examples of CD146 staining for (a) a metaplastic 
carcinoma and (b) an invasive adenocarcinoma.Page 4 of 14
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Histoclinical correlations of breast cancers according to CD146 expression
Characteristic DNA microarray Tissue microarray
CD146-rich (n = 113) P value* CD146+ (n = 45) P value*
Age
< 45 years 36/74 NS 9/85 NS
≥ 45 years 59/115 36/549
Pathological type
Ductal 92/179 NS 36/472 NS
Lobular 17/43 2/77
Tubular 1/40
Medullar 1/8
Mixed 2/25
Other 4/26
Molecular subtype
Basal 44/67 <0.0001
ERBB2 15/31
Luminal 32/93
Normal 16/21
Scarff Bloom and Richardson grade
I + II 26/77 <0.0001 18/463 <0.0001
III 87/149 27/163
Tumor size
< 20 28/53 NS 17/281 NS
≥ 20 54/122 26/347
Pathological axillary lymph node status
Negative 52/90 NS
Positive 54/122
Immunohistochemistry estrogen receptor status
Negative 72/119 <0.0001 28/141 <0.0001
Positive 41/108 13/460
Immunohistochemistry progesterone receptor status
Negative 83/137 <0.0001 35/208 <0.0001
Positive 30/90 9/362
Immunohistochemistry ERBB2 status
Negative 83/169 NS 40/515 NS
Positive 19/36 2/46
Immunohistochemistry estrogen receptor/progesterone receptor/ERBB2 status
Triple negative 25/76 <0.0001
Other 13/425
Immunohistochemistry p53 statusPage 5 of 14
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indicated a statistically significant difference in the overall sur-
vival time between patients with positive and negative CD146
status, as assayed with immunohistochemistry on tissue
microarrays (P = 0.0104, log-rank test; Figure 3a); after 5
years, survival rates no longer indicated a difference between
the two subgroups. In triple-negative tumors there was a non-
statistically significant trend towards a shorter overall survival
in CD146-positive tumors during the first 3 years (Figure 3b).
An increased risk of death before 5 years is therefore associ-
ated with CD146 expression in the epithelial compartment of
breast cancer tissues.
CD146 is a marker of mesenchymal-like breast cancer 
cell lines
DNA microarray analyses of 34 mammary cell lines [34] show
the strong expression of CD146 in MDA-MB-231 and
Hs578T cell lines, and its low expression in MCF-7, ZR-75-30
and MDA-MB-453 cells. An expanded view of the hierarchical
clustering shows that CD146 is included in a stromal/mesen-
chymal gene cluster, near the basal gene cluster, and is over-
expressed in mesenchymal-like cell lines as compared with
other cell lines (Figure 4).
We confirmed these results by flow cytometry analyses. Two
subgroups of human mammary cancer cell lines were easily
distinguishable on the basis of CD146 expression (Figure 5):
MCF-7, ZR-75-30, BrCA-MZ-02, MDA-MB-453 and T47-D
cell lines, which display epithelial characteristics, expressed
CD146 at low levels (CD146-); and oppositely, MDA-MB-231,
Hs578T, Sum159PT, MDA-MB-436 and BT-549 cell lines,
which display mesenchymal characteristics, also expressed
high levels of CD146 (CD146+). Of note, the T47D cell line
was negative for CD146 protein expression while the mRNA
was detected in microarray and RT-PCR analyses, thus sug-
gesting the possibility of post-transductional regulation.
Downmodulation of CD146 expression in the MDA-MB-
231 mammary cancer cell line results in decreased 
migration
For further experiments, the MDA-MB-231 cell line was used
as a prototypic mesenchymal and invasive cell line, spontane-
ously expressing high levels of CD146.
CD146 expression was downmodulated by transient transfec-
tion with siRNAs. The two most efficient siRNAs (si78 and
si79) produced a significant reduction in the levels of CD146
mRNA and protein (Figure 6a,b) when compared with three
Negative 14/330 0.0046
Positive 15/124
Immunohistochemistry Bcl2 status
Negative 22/138 <0.0001
Positive 18/388
Immunohistochemistry CD44 status
Negative 1/136 0.0225
Positive 17/283
Immunohistochemistry epithelial growth factor receptor status
Negative 3/284 0.00011
Positive 9/81
Immunohistochemistry GATA3 status
Negative 30/203 0.00032
Positive 10/313
Immunohistochemistry Moesin status
Negative 4/339 <0.0001
Positive 13/65
Immunohistochemistry P-cadherin status
Negative 1/199 0.00021
Positive 14/173
*To assess differences in clinicopathologic features between the two groups of patients, Fisher's exact test was used for qualitative variables with 
discrete categories.
Table 1 (Continued)
Histoclinical correlations of breast cancers according to CD146 expressionPage 6 of 14
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transfected with control siRNAs that respectively target green
fluorescent protein or differ from si78 by four nucleotides in its
sequence (si78mut).
The downregulation of CD146 expression was associated
with reduced abilities to migrate in a transwell assay in
response to 10% FCS when compared with wild-type cells or
mock-transfected cells (Figure 6c). In addition, exposure of
wild-type MDA-MB-231 cells to S-endo1 anti-CD146 mAb
resulted in a decreased migration (n = 4; data not shown); in
one additional experiment, the S-endo1 mAb had the same
effect on the Sum159PT cell line (data not shown). Down-
modulation of CD146 expression also resulted in a significant
decrease of MDA-MB-231 transmigration through the estab-
lished HBMEC human endothelial cell line (Figure 6d). Finally,
MDA-MB-231 cells also displayed a reduced ability to heal a
wound, following CD146 downmodulation (Figure 6e,f).
Downmodulation of CD146 expression results in 
changes in the expression signature of the MDA-MB-231 
breast cancer cell line
We generated two MDA-MB-231-derived cell lines (TI6194
and TI6196) that stably expressed 29mer shRNAs against
CD146. Knockdown of CD146 was confirmed at the mRNA
level using quantitative RT-PCR (see Figure S1a in Additional
data file 5) and whole-genome DNA microarrays (Table 2).
Phenotypic analysis of CD146 expression showed that the
mean fluorescence intensity of CD146 was reduced more
than 80%, the inhibition being greater in the TI6194 cell line
(see Figure S1b in Additional data file 5). Empty plasmid or
shRNA directed against green fluorescent protein did not
affect CD146 expression. Migration in a transwell assay of
TI6194 and TI6196 cells decreased accordingly (data not
shown).
Wild-type, mock-transfected and TI6194 and TI6196 trans-
fected cells were profiled using whole-genome DNA microar-
rays to identify genes whose expression was modified by
CD146 downregulation. The results are shown in a volcano
plot (see Additional data file 6). Supervised analysis using the
t test revealed 363 probe sets differentially expressed (P <
0.05 with false discovery rate correction). Among these, 13
probe sets (Table 2) displayed a ≥ 2-fold decrease associated
with CD146 downregulation. These 13 probe sets repre-
sented seven unique genes including MCAM/CD146. With a
less stringent cutoff value (≥ 1.5-fold change), 28 probe sets
– representing 21 unique genes – were downregulated in the
Figure 2
CD146 mRNA expression in human primary breast tumors ssion in human primary breast tumors. (a) Hierarchical clustering of 227 breast cancer tissue samples and 14,486 genes/
Expressed Sequence Tags based on mRNA expression levels. Each row represents a gene, and each column represents a tumor. The expression 
level of each gene in a single tumor is relative to its median abundance across all tumors and is depicted according to a color scale shown at the 
bottom. Red and green, expression levels respectively above and below the median. The magnitude of deviation from the median is represented by 
the color saturation. The dendrogram of samples (above matrix) represents overall similarities in gene expression profiles and is magnified in (b), 
colored bars to the left, locations of seven gene clusters of interest. The stromal/vascular gene cluster (orange bar) includes MCAM. ER, estrogen 
receptor. (b) Dendrogram of breast cancer samples. (c) Expanded view of CD146/MCAM expression. Also see Additional data file 4.Page 7 of 14
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set was upregulated in these cell lines. Quantitative RT-PCR
confirmed these results for 15 out of the 21 tested genes,
failed for three genes, and did not identify any significant dif-
ferential expression for three genes (Table 2).
To further explore mRNA expression changes related to the
downmodulation in CD146, we used multiplex quantitative RT-
PCR. We focused the analysis on the expression of 184
genes involved in migration, adhesion and cytoskeleton. The
genes whose expression was significantly modulated in this
screening belong to different protein families, including
integrins (α2, α6, β3, β4 subunits), extracellular matrix or
structural proteins, transcription factors, and molecules
involved in signal transduction (Table 2). The expression of
Vimentin, a mesenchymal marker (like fibronectin 1), was
downregulated in the TI6194 cell line, which is the engineered
MDA-MB-231 cell line with the lowest expression of CD146.
Interestingly, the downregulation of CD146 expression was
associated with a downregulation of the proto-oncogene
VAV1, of CXCR4 (the receptor for CXCL12) and of the chem-
okine CCL5. Only few transcripts were upregulated: among
these transcripts, DEF6, CXCL10 and BCL7A are associated
with a lower tumorigenicity.
There was a good correlation between the results obtained
with the two expression profiling approaches. Out of the 99
genes represented on multiplex plates and Affymetrix microar-
rays (among the 18,041 probe sets retained after the filtering
step), 85 genes (86%) displayed concordant results accord-
ing to the two approaches – whereas only 14 genes showed
discordant results. This discordance may be related to the dif-
ference in sensitivity of the two techniques, as well as to differ-
ent transcripts tested. The downregulation of transcripts for
CXCR4, CD44, ICAM1 and integrin α6 was confirmed by
cytometry analyses, and the upregulation of CXCL10 was
confirmed using an antibody array (data not shown).
Discussion
MCAM or CD146, a cell–cell or cell–matrix adhesion mole-
cule, was first described in melanomas where a high level of
CD146 expression is associated with a poor prognosis [35].
More recently, the high expression of CD146 has also been
associated with metastatic progression in prostate cancer
[14] and ovarian cancer [16]. A previous report supports a
tumor suppressor role rather than a prometastatic role for
CD146 in breast cancer pathogenesis [23].
Tissue microarray analysis indicates that only a small subset of
human primary tumors expresses CD146 proteins in the epi-
thelial compartment. CD146 expression correlates with a high
tumor grade and triple-negative receptor status. A correlation
was also observed with epithelial growth factor receptor, P-
cadherin, p53, Moesin, Bcl2 and GATA3 expression. All of
these characteristics are associated with the basal phenotype.
In the present study of 635 breast tumors, CD146 expression
is associated with a poor overall survival with a follow-up cutoff
point at 5 years.
As revealed by DNA microarrays, CD146 belongs to a stro-
mal/mesenchymal signature and is expressed in human mam-
mary tumor cell lines that can be classified in the basal-B
subtype [36]. Then, similarly to other tumor types, CD146
expression is associated with poor prognosis in breast can-
cers. A possible explanation for this association is the role of
Figure 3
Specific survival of patients with CD146- and CD146+ tumorsic urvival of patients with CD146- and CD146+ tumors. 
CD146 expression was defined using immunohistochemistry on tissue 
microarrays. (a) All tumors. (b) Estrogen receptor-negative/progester-
one receptor-negative/ERBB2-negative (triple-negative) tumors.Page 8 of 14
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expression and the presence of CD44+/CD24low cells in
breast cancer cell lines (data not shown) is consistent with
previous observations at the mRNA level in cell lines [36], and
supports the hypothesis that CD146 expression may be asso-
ciated with the metastatic potential of breast tumor cells [37].
Downmodulation of CD146 expression by siRNA or shRNA
approaches in cell lines that spontaneously express a high
level of CD146 mostly resulted in a decreased migration in
three distinct assays, at least one of which involves heterotypic
cell–cell interactions. These results in breast cancer are con-
sistent with previously reported results for melanoma cells
[38,39]. Although the exact function of CD146 on different
cell types remains elusive, these observations – together with
published results for lymphocytes [8] – reinforce the hypothe-
sis that CD146 is an actor of cell migration. Witze and col-
leagues recently showed that CD146 is recruited with actin,
myosin IIB and Frizzled into an intracellular structure, which
Figure 4
CD146 mRNA expression in human breast cancer cell lines ssion in human breast cancer cell lines. (a) Hierarchical clustering of 34 mammary cell lines and 13,976 genes/Expressed 
Sequence Tags based on mRNA expression levels. The legend is similar to Figure 2. Colored bars to the left, locations of four gene clusters of inter-
est. The stromal/mesenchymal gene cluster (orange bar) includes MCAM. ER, estrogen receptor. (b) Dendrogram of cell lines. *Cell lines analyzed 
in the present study by flow cytometry for CD146 expression (low expression, MCF-7, ZR-75-30 and MDA-MB-453; high expression, MDA-MB-231, 
Hs578T and MCF-10A). (c) Expanded view of the stromal/mesenchymal gene cluster, which includes the four probe sets representing CD146/
MCAM. Genes are referenced by their HUGO abbreviation as used in Entrez Gene.
Figure 5
CD146 expression in breast cancer cell lines ion in breast cancer ce l lines. Values indicate the 
specific mean fluorescence intensity (sMFI) ± standard error of the 
mean in at least six independent experiments, using the P1H12 mAb. 
The sMFI was defined as the ratio of the mean fluorescence intensity 
for the considered mAb over the mean fluorescence intensity obtained 
with the appropriate isotypic control.Page 9 of 14
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Downmodulation of CD146 expression and migration abilities of the MDA-MB-231 cell lineodulation of CD146 expression and migration abilities of the MDA MB-231 cell line. (a) CD146 mRNA expression in the MDA-MB-231 
cell line 72 hours after transfection with siRNAs targeting CD146. Two different siRNAs (si78 and si79) and two controls (si78mut and siGFP) were 
used. CD146mRNA expression was normalized to GAPDH and expressed relatively to the native cells (arbitrarily 100%). (b) Protein expression (PE) 
measured by flow cytometry, one representative experiment. (c) Chemotactic migration evaluated after 24 hours, using uncoated Boyden chambers 
and 10% FCS as chemoattractant. (d) Transmigration through the established human endothelial HBMEC cell line. (e) and (f) Wound healing 
assay. (e) Wound healing repair was evaluated after 24 hours; percentage of the initial wound surface repaired after 24 hours was estimated using 
ImageJ software. (f) A representative experiment of wound healing: MDA-MB-231 cells were transfected with siRNAs and, 3 days after transfection, 
a cell-free area (wound) was created in confluent cultures (t = 0); cells were allowed to migrate for 24 hours (t = 24) before image analysis. For (c), 
(d) and (e) results are expressed relative to the results obtained with the mutated si78 RNA (arbitrarily 100%) and represent the mean ± standard 
error of the mean of four independent experiments (except for (d), which represents two experiments).
accumulates at the cell periphery and is associated with mem-
brane retraction in response to Wnt5a [39].
Changes in molecular signatures following downmodulation of
CD146 expression support the contribution of indirect mech-
anisms in decreased migration abilities. A small subset of
genes appeared to be mostly downmodulated. Some of these
genes are obvious players in cell migration, including CD44
[40] and FPR1 [41]. Concomitantly with CD146 downmodu-
lation, we observed a downmodulation of CXCR4 and CCL5.
CXCR4 is known to be upregulated in breast tumors; neutral-
izing the interaction of CXCL12 with CXCR4 significantly
reduces breast cancer cell metastases in vivo [42], as does
the repression of CCL5 that has anti-migratory effects [43].
Overexpression of CCL5 in MDA-MB-231 cells enhances
their metastatic potential [44].
Other modulated genes are involved in oncogenic processes:
CYP1B1 is associated with adverse prognosis [45], and
VAV1 is a known proto-oncogene. Among the few upregu-
lated genes detected with quantitative RT-PCR, BCL7A has
been classified as a tumor suppressor gene [46], whilePage 10 of 14
(page number not for citation purposes)
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Table 2
Genes modulated as a consequence of CD146 downmodulation
Symbol Accession number Fold change P value (t test)
DNA microarray
LIPG [GenBank:NM_006033] -6.75 0.02749
MCAM [GenBank:NM_006500] -3.61 0.00084
FPR1 [GenBank:NM_002029] -2.88 0.03159
CYP1B1 [GenBank:NM_000104] -2.73 0.03208
FN1 [GenBank:NM_212475] -2.48 0.00657
SORCS2 [GenBank:NM_020777] -2.17 0.0314
FLJ20160 [GenBank:NM_017694] -1.74 0.01431
LTBP1 [GenBank:NM_206943] -1.72 0.03606
HES1 [GenBank:NM_005524] -1.7 0.04315
AIM1 [GenBank:NM_001624] -1.63 0.00758
MFAP2 [GenBank:NM_002403] -1.58 0.04437
HIPK2 [GenBank:NM_022740] -1.55 0.00781
CALD1 [GenBank:NM_033138] -1.51 0.0113
NAV1 [GenBank:NM_020443] -1.5 0.00481
NFIC [GenBank:NM_005597] -1.5 0.0275
TGFBI [GenBank:NM_000660] -1.85* 0.03459
TRIM59 [GenBank:NM_173084] -1.76* 0.01626
NFAT5 [GenBank:NM_138714] -1.51* 0.04496
APCDD1L [GenBank:NM_153360] -2.38** 0.01035
GARNL4 [GenBank:NM_001100398] -1.96** 0.04209
PCMTD1 [GenBank:NM_052937] -1.59** 0.0362
Multiplex quantitative RT-PCR
KALRN [GenBank:NM_003947] -10 0.02973
PREX1 [GenBank:NM_020820] -8.93 0.01711
VAV1 [GenBank:NM_005428] -7.94 0.00688
FGD4 [GenBank:NM_139241] -4.63 0.00318
RHOV [GenBank:NM_133639] -4.03 0.03116
CCL5 [GenBank:NM_002985] -3.88 0.00536
ITGB3 [GenBank:NM_000212] -3.61 0.00187
CXCL16 [GenBank:NM_022059] -2.92 0.00252
THBS1 [GenBank:NM_003246] -2.66 0.01279
CXCR4 [GenBank:NM_001008540] -2.21 0.00259
ITGB4 [GenBank:NM_001005731] -2.15 0.01068
CD44 [GenBank:NM_000610] -1.92 0.00141
ITGA2 [GenBank:NM_002203] -1.86 0.00191
ROCK2 [GenBank:NM_004850] -1,80 0.00004
ITGA6 [GenBank:NM_000210] -1.63 0.00274
VIM [GenBank:NM_003380] -1.45*** 0.04761
ARHGEF11 [GenBank:NM_198236] 1.67 0.00288
BCL7A [GenBank:NM_001024808] 1.69 0.02473
DEF6 [GenBank:NM_022047] 2.05 0.00946
TNK2 [GenBank:NM_005781] 2.18 0.00222
CXCL10 [GenBank:NM_001565] 2.51 0.03645
*Not validated by quantitative RT-PCR. **Quantitative RT-PCR not available.***Observed only with the TI6194 cell line.
Breast Cancer Research    Vol 11 No 1    Zabouo et al.CXCL10 mediates a thymus-dependent antitumor response in
vivo [47].
Downmodulation of CD146 induces the downmodulation of
genes such as vimentin, fibronectin and thrombospondin,
which are mesenchymal markers; it also induces downmodu-
lation of LTBP1, a protein expressed in stromal cells that trig-
gers the biological activity of tumor growth factor beta.
Altogether, these observations suggest that CD146 down-
modulation is associated with the reversal of several biological
characteristics associated with an aggressive phenotype.
Conclusion
We provide evidence that CD146 is involved in breast cancer
cell line motility and is associated with the basal subtype of pri-
mary breast cancers. In this picture, CD146 appears as a pro-
metastatic factor associated with poor-prognosis histoclinical
features, rather than as a tumor suppressor gene. Because
CD146 downmodulation is associated with the reversal of
several biological characteristics leading to a less aggressive
phenotype, treatments targeting CD146 could be considered
in breast cancers as in other malignancies.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GZ and AM-I contributed equally. GZ and AM-I designed and
performed in vitro experiments, and wrote the manuscript. PF
and FB performed and interpreted DNA microarrays experi-
ments. JJ performed and interpreted tissue microarray experi-
ments. TM helped in the validation of siRNA. BE performed
statistical analyses. DB reviewed and discussed the results.
CC designed experiments, reviewed results, and wrote and
edited the manuscript.
Authors' information
The present work was presented in part at the 2007 Annual
Meeting of the American Association for Cancer Research in
Los Angeles, USA (abstract # 5711).
Additional files
Acknowledgements
The authors are grateful to all personnel in the Département de Bio-
pathologie and the Centre de Ressources Biologiques en Oncologie 
(Biological Resource Centre in Oncology, Tumor Cell and Tissue Bank) 
at Institut Paoli-Calmettes for access to the tumor samples, to José 
Adélaide for providing some of the human mammary cancer cell lines, to 
Véronique Jellade and Dominique Genre (Bureau d'Etudes Cliniques, 
Clinical Research Office) for access to patient long-term follow-up, to 
Michele Batoz (Inserm U 576 Régulations des réactions immunitaires et 
inflammatoires, Nice) for providing microwell plates used for quantitative 
RT-PCR assays, and to Emmanuelle Charafe-Jauffret (UMR891), 
Françoise Dignat-George (Inserm U608, Marseille), Frédéric Vély 
(Inserm U608), Marc Lopez (UMR891), Ali Badache (UMR891), Michel 
Aurrand-Lions (UMR891) and Dominique Dunon (UPMC, Paris) for 
helpful discussions.
The present work was supported in part by Institut Paoli-Calmettes, and 
by a grant to CC and the cancéropôle PACA from the Institut National 
du Cancer. GZ is a recipient of the fellowship from the Ministère de la 
Recherche, de l'Enseignement Supérieur et des Nouvelles Technolo-
The following Additional files are available online:
Additional file 1
A Word file containing information about the mAbs used 
in the present study.
See http://www.biomedcentral.com/content/
supplementary/bcr2215-S1.doc
Additional file 2
A Word file containing information about the sequences 
of primers used in quantitative RT-PCR and sequences 
of siRNAs and shRNAs.
See http://www.biomedcentral.com/content/
supplementary/bcr2215-S2.doc
Additional file 3
A Word file containing a table that presents the genes 
tested by quantitative RT-PCR.
See http://www.biomedcentral.com/content/
supplementary/bcr2215-S3.doc
Additional file 4
A Word file containing a table that presents the genes of 
the stromal cluster.
See http://www.biomedcentral.com/content/
supplementary/bcr2215-S4.doc
Additional file 5
An Adobe file containing a figure showing the 
downmodulation of CD146 in MDA-MB-231 cells with 
shRNAs targeting CD146.
See http://www.biomedcentral.com/content/
supplementary/bcr2215-S5.pdf
Additional file 6
An Adobe file containing a figure showing the mRNA 
expression levels between the wild-type and the mock-
transfected MDA-MB-231 cell lines displayed as a 
volcano plot.
See http://www.biomedcentral.com/content/
supplementary/bcr2215-S6.pdfPage 12 of 14
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/11/1/R1gies (France), and from the Association pour la Recherche sur le Can-
cer.
References
1. McSherry EA, Donatello S, Hopkins AM, McDonnell S: Molecular
basis of invasion in breast cancer.  Cell Mol Life Sci 2007,
64:3201-3218.
2. Lehmann JM, Riethmuller G, Johnson JP: MUC18, a marker of
tumor progression in human melanoma, shows sequence
similarity to the neural cell adhesion molecules of the immu-
noglobulin superfamily.  Proc Natl Acad Sci USA 1989,
86:9891-9895.
3. Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP:
Genomic organization of the melanoma-associated glycopro-
tein MUC18: implications for the evolution of the immunoglob-
ulin domains.  Proc Natl Acad Sci USA 1993, 90:8514-8518.
4. Shih IM, Speicher D, Hsu MY, Levine E, Herlyn M: Melanoma cell–
cell interactions are mediated through heterophilic Mel-CAM/
ligand adhesion.  Cancer Res 1997, 57:3835-3840.
5. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A,
Sampol J, Dignat-George F: Identification of CD146 as a compo-
nent of the endothelial junction involved in the control of cell–
cell cohesion.  Blood 2001, 98:3677-3684.
6. Delorme B, Ringe J, Gallay N, Le Vern Y, Kerboeuf D, Jorgensen C,
Rosset P, Sensebe L, Layrolle P, Haupl T, Charbord P: Specific
plasma membrane protein phenotype of culture-amplified and
native human bone marrow mesenchymal stem cells.  Blood
2008, 111:2631-2635.
7. Chan B, Sinha S, Cho D, Ramchandran R, Sukhatme VP: Critical
roles of CD146 in zebrafish vascular development.  Dev Dyn
2005, 232:232-244.
8. Guezguez B, Vigneron P, Lamerant N, Kieda C, Jaffredo T, Dunon
D: Dual role of melanoma cell adhesion molecule (MCAM)/
CD146 in lymphocyte endothelium interaction: MCAM/CD146
promotes rolling via microvilli induction in lymphocyte and is
an endothelial adhesion receptor.  J Immunol 2007,
179:6673-6685.
9. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Sag-
gio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P:
Self-renewing osteoprogenitors in bone marrow sinusoids
can organize a hematopoietic microenvironment.  Cell 2007,
131:324-336.
10. Pickl WF, Majdic O, Fischer GF, Petzelbauer P, Fae I, Waclavicek
M, Stockl J, Scheinecker C, Vidicki T, Aschauer H, Johnson JP,
Knapp W: MUC18/MCAM (CD146), an activation antigen of
human T lymphocytes.  J Immunol 1997, 158:2107-2115.
11. Tsuchiya S, Tsukamoto Y, Furuya M, Hiroi S, Miki N, Sasaki F, Taira
E: Gicerin, a cell adhesion molecule, promotes the metastasis
of lymphoma cells of the chicken.  Cell Tissue Res 2003,
314:389-397.
12. Tsukamoto Y, Sakaiuchi T, Hiroi S, Furuya M, Tsuchiya S, Sasaki F,
Miki N, Taira E: Expression of gicerin enhances the invasive and
metastatic activities of a mouse mammary carcinoma cell line.
Int J Oncol 2003, 23:1671-1677.
13. Schlagbauer-Wadl H, Jansen B, Muller M, Polterauer P, Wolff K,
Eichler HG, Pehamberger H, Konak E, Johnson JP: Influence of
MUC18/MCAM/CD146 expression on human melanoma
growth and metastasis in SCID mice.  Int J Cancer 1999,
81:951-955.
14. Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW:
Increased expression of MUC18 correlates with the metastatic
progression of mouse prostate adenocarcinoma in the TRAMP
model.  J Urol 2005, 173:1778-1783.
15. Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL, Wu
MW: Ectopical expression of human MUC18 increases metas-
tasis of human prostate cancer cells.  Gene 2004,
327:201-213.
16. Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brug-
nara S, Zeni B, Griso C, Pegoraro C, Zannoni M, Gariboldi M, Bal-
ladore E, Mezzanzanica D, Canevari S, Barbareschi M: M-CAM
expression as marker of poor prognosis in epithelial ovarian
cancer.  Int J Cancer 2006, 119:1920-1926.
17. Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petersen I:
Expression of the cell adhesion molecule CD146/MCAM in
non-small cell lung cancer.  Anal Cell Pathol 2003, 25:77-81.
18. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas
JM, Feng X, Bar-Eli M: Fully human antibodies to MCAM/
MUC18 inhibit tumor growth and metastasis of human
melanoma.  Cancer Res 2002, 62:5106-5114.
19. Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L,
Luo D, Liu Q, Mann K, Bader BL: A novel anti-CD146 monoclonal
antibody, AA98, inhibits angiogenesis and tumor growth.
Blood 2003, 102:184-191.
20. Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M:
Immunization against MUC18/MCAM, a novel antigen that
drives melanoma invasion and metastasis.  Gene Ther 2007,
14:316-323.
21. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD: Circulating
endothelial cells, endothelial progenitor cells, and endothelial
microparticles in cancer.  Neoplasia 2006, 8:79-88.
22. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S,
Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C,
Bonnier P, Charpin C: Poor prognosis in breast carcinomas cor-
relates with increased expression of targetable CD146 and c-
Met and with proteomic basal-like phenotype.  Hum Pathol
2007, 38:830-841.
23. Shih LM, Hsu MY, Palazzo JP, Herlyn M: The cell–cell adhesion
receptor Mel-CAM acts as a tumor suppressor in breast carci-
noma.  Am J Pathol 1997, 151:745-751.
24. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J,
Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens P,
Mozziconacci MJ, Houlgatte R, Birnbaum D, Jacquemier J: Distinct
and complementary information provided by use of tissue and
DNA microarrays in the study of breast tumor markers.  Am J
Pathol 2002, 161:1223-1233.
25. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauf-
fret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J,
Maraninchi D, Viens P, Birnbaum D, Bertucci F: Protein expres-
sion profiling identifies subclasses of breast cancer and pre-
dicts prognosis.  Cancer Res 2005, 65:767-779.
26. Mobus VJ, Moll R, Gerharz CD, Kieback DG, Merk O, Runnebaum
IB, Linner S, Dreher L, Grill HJ, Kreienberg R: Differential charac-
teristics of two new tumorigenic cell lines of human breast car-
cinoma origin.  Int J Cancer 1998, 77:415-423.
27. Schweitzer KM, Vicart P, Delouis C, Paulin D, Drager AM, Langen-
huijsen MM, Weksler BB: Characterization of a newly estab-
lished human bone marrow endothelial cell line: distinct
adhesive properties for hematopoietic progenitors compared
with human umbilical vein endothelial cells.  Lab Invest 1997,
76:25-36.
28. Imbert AM, Belaaloui G, Bardin F, Tonnelle C, Lopez M, Chaban-
non C: CD99 expressed on human mobilized peripheral blood
CD34+ cells is involved in transendothelial migration.  Blood
2006, 108:2578-2586.
29. ImageJ Image Processing and Analysis in Java   [http://
rsb.info.nih.gov]
30. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ,
Scherf U, Speed TP: Exploration, normalization, and summa-
ries of high density oligonucleotide array probe level data.
Biostatistics 2003, 4:249-264.
31. Chen JJ, Wang SJ, Tsai CA, Lin CJ: Selection of differentially
expressed genes in microarray data analysis.  Pharmacoge-
nomics J 2007, 7:212-220.
32. The Comprehensive R Archive Network   [http://www.cran.r-
project.org]
33. Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamen-
schikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale Al,
Brown PO, Botstein D: Molecular portraits of human breast
tumours.  Nature 2000, 406:747-752.
34. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J,
Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci
F: Gene expression profiling of breast cell lines identifies
potential new basal markers.  Oncogene 2006, 25:2273-2284.
35. Shih IM, Elder DE, Hsu MY, Herlyn M: Regulation of Mel-CAM/
MUC18 expression on melanocytes of different stages of
tumor progression by normal keratinocytes.  Am J Pathol 1994,
145:837-845.
36. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L,
Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S,
Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DJ,
Waldman FM, McCormick F, Dickson RB, Johnson MD, LippmanPage 13 of 14
(page number not for citation purposes)
Breast Cancer Research    Vol 11 No 1    Zabouo et al.M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer
cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 2006, 10:515-527.
37. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke
MF: Prospective identification of tumorigenic breast cancer
cells.  Proc Natl Acad Sci USA 2003, 100:3983-3988.
38. Watson-Hurst K, Becker D: The role of N-cadherin, MCAM and
beta3 integrin in melanoma progression, proliferation, migra-
tion and invasion.  Cancer Biol Ther 2006, 5:1375-1382.
39. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG: Wnt5a con-
trol of cell polarity and directional movement by polarized
redistribution of adhesion receptors.  Science 2008,
320:365-369.
40. Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS: CD44 crosslink-
ing-mediated matrix metalloproteinase-9 relocation in breast
tumor cells leads to enhanced metastasis.  Int J Oncol 2007,
31:1119-1126.
41. Huang J, Hu J, Bian X, Chen K, Gong W, Dunlop NM, Howard OM,
Wang JM: Transactivation of the epidermal growth factor
receptor by formylpeptide receptor exacerbates the malignant
behavior of human glioblastoma cells.  Cancer Res 2007,
67:5906-5913.
42. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME,
McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar
A, Verastegui E, Zlotnik A: Involvement of chemokine receptors
in breast cancer metastasis.  Nature 2001, 410:50-56.
43. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE: Novel c-
MYC target genes mediate differential effects on cell prolifer-
ation and migration.  EMBO Rep 2007, 8:70-76.
44. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW,
Richardson AL, Polyak K, Tubo R, Weinberg RA: Mesenchymal
stem cells within tumour stroma promote breast cancer
metastasis.  Nature 2007, 449:557-563.
45. Haas S, Pierl C, Harth V, Pesch B, Rabstein S, Bruning T, Ko Y,
Hamann U, Justenhoven C, Brauch H, Fischer HP: Expression of
xenobiotic and steroid hormone metabolizing enzymes in
human breast carcinomas.  Int J Cancer 2006, 119:1785-1791.
46. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Comman-
deur S, Mulder AA, Velden PA van der, Vermeer MH, Willemze R,
Yan PS, Huang TH, Tensen CP: Epigenetic profiling of cutane-
ous T-cell lymphoma: promoter hypermethylation of multiple
tumor suppressor genes including BCL7a, PTPRG, and p73.  J
Clin Oncol 2005, 23:3886-3896.
47. Luster AD, Leder P: IP-10, a -C-X-C- chemokine, elicits a potent
thymus-dependent antitumor response in vivo.  J Exp Med
1993, 178:1057-1065.Page 14 of 14
(page number not for citation purposes)
